[{"id":"27333119-b7fd-424a-9cb7-3d186e837736","acronym":"","url":"https://clinicaltrials.gov/study/NCT06965114","created_at":"2025-06-14T13:57:06.110Z","updated_at":"2025-06-14T13:57:06.110Z","phase":"Phase 1/2","brief_title":"Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment","source_id_and_acronym":"NCT06965114","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Ojemda (tovorafenib) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2025-06-11"},{"id":"7d78cd12-55c9-4664-9e5c-f58906c32c60","acronym":"","url":"https://clinicaltrials.gov/study/NCT06311227","created_at":"2024-03-15T17:37:14.823Z","updated_at":"2025-02-25T14:42:47.183Z","phase":"Phase 2","brief_title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT06311227","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • TP53","pipe":" | ","alterations":" TP53 mutation","tags":["BRAF • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2027","study_completion_date":" 05/20/2027","last_update_posted":"2025-02-14"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"d8485b72-fd46-4a36-8dc8-65fce07dac67","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841723","created_at":"2021-01-18T08:12:27.496Z","updated_at":"2024-07-02T16:34:27.123Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT01841723","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/30/2013","start_date":" 04/30/2013","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-11"},{"id":"1c9f6138-8d9a-47fc-a239-63c21b0bb4fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04815356","created_at":"2021-03-25T12:52:31.393Z","updated_at":"2024-07-02T16:34:38.088Z","phase":"Phase 1","brief_title":"Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant","source_id_and_acronym":"NCT04815356","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • JCAR018 • anti-CD22 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/01/2036","primary_completion_date":" 12/01/2036","study_txt":" Completion: 12/01/2036","study_completion_date":" 12/01/2036","last_update_posted":"2024-06-05"},{"id":"4695b874-0dda-42f4-8cd0-07e18a81aa76","acronym":"","url":"https://clinicaltrials.gov/study/NCT00923013","created_at":"2021-01-18T03:34:20.113Z","updated_at":"2024-07-02T16:34:38.035Z","phase":"Phase 2","brief_title":"Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia","source_id_and_acronym":"NCT00923013","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • ITGAX","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 10/20/2008","start_date":" 10/20/2008","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"7729abda-f09b-4e1d-8f6d-26d789073f5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00412594","created_at":"2021-01-18T01:26:56.389Z","updated_at":"2024-07-02T16:35:02.663Z","phase":"Phase 2","brief_title":"Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia","source_id_and_acronym":"NCT00412594","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cladribine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 06/10/2004","start_date":" 06/10/2004","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"},{"id":"015bee1f-dfaa-4768-9837-b466448d181f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06340737","created_at":"2024-04-01T19:42:38.783Z","updated_at":"2024-07-02T16:35:11.716Z","phase":"Phase 1","brief_title":"AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas","source_id_and_acronym":"NCT06340737","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 04/01/2031","primary_completion_date":" 04/01/2031","study_txt":" Completion: 04/01/2031","study_completion_date":" 04/01/2031","last_update_posted":"2024-04-03"},{"id":"acdeafe3-7008-41f0-8f96-f453b266a334","acronym":"","url":"https://clinicaltrials.gov/study/NCT01588015","created_at":"2021-01-18T06:46:27.904Z","updated_at":"2024-07-02T16:35:12.025Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT01588015","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" PD-1 expression","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promune (agatolimod)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/29/2012","start_date":" 10/29/2012","primary_txt":" Primary completion: 02/02/2024","primary_completion_date":" 02/02/2024","study_txt":" Completion: 02/02/2024","study_completion_date":" 02/02/2024","last_update_posted":"2024-04-02"},{"id":"f9804601-1b5e-4001-940c-6e9301ecc5f3","acronym":"CP-MGD024-01","url":"https://clinicaltrials.gov/study/NCT05362773","created_at":"2022-05-05T15:53:53.535Z","updated_at":"2024-07-02T16:35:23.328Z","phase":"Phase 1","brief_title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT05362773 - CP-MGD024-01","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGD024"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-01-17"},{"id":"a507c28a-87c0-4461-a856-ff35aefcb93f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01815749","created_at":"2021-01-18T08:03:43.924Z","updated_at":"2024-07-02T16:35:24.544Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01815749","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • CD34","pipe":"","alterations":" ","tags":["EGFR • CD34"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/08/2013","start_date":" 10/08/2013","primary_txt":" Primary completion: 01/09/2018","primary_completion_date":" 01/09/2018","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-01-04"},{"id":"2e1f45d7-114f-4454-9867-53cc8e8641d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681105","created_at":"2021-01-19T20:46:40.489Z","updated_at":"2024-07-02T16:35:25.698Z","phase":"Phase 1","brief_title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","source_id_and_acronym":"NCT04681105","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/18/2020","start_date":" 11/18/2020","primary_txt":" Primary completion: 05/05/2026","primary_completion_date":" 05/05/2026","study_txt":" Completion: 05/05/2026","study_completion_date":" 05/05/2026","last_update_posted":"2023-12-20"},{"id":"4f4288df-695a-47f7-a6a0-96528472a3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00321555","created_at":"2021-01-18T01:06:25.835Z","updated_at":"2024-07-02T16:35:29.257Z","phase":"Phase 2","brief_title":"LMB-2 to Treat Hairy Cell Leukemia","source_id_and_acronym":"NCT00321555","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IL2RA positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-2"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/02/2006","start_date":" 05/02/2006","primary_txt":" Primary completion: 08/24/2016","primary_completion_date":" 08/24/2016","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-11-14"},{"id":"3bafa6d0-29f9-4e0c-8308-7ec0cbbe6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03010358","created_at":"2021-01-18T14:49:09.492Z","updated_at":"2024-07-02T16:35:40.703Z","phase":"Phase 1/2","brief_title":"Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03010358","lead_sponsor":"Alexey Danilov, MD","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • entospletinib (GS-9973)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 04/29/2021","primary_completion_date":" 04/29/2021","study_txt":" Completion: 04/29/2021","study_completion_date":" 04/29/2021","last_update_posted":"2023-08-08"},{"id":"e20d140c-2937-4561-a913-76a4c61c5fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01711632","created_at":"2021-01-17T18:01:40.116Z","updated_at":"2024-07-02T16:35:41.371Z","phase":"Phase 2","brief_title":"BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01711632","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MAPK8","pipe":" | ","alterations":" RAS mutation","tags":["MAPK8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-08-01"},{"id":"613e6d83-8a24-4773-9fa7-ac0078156fbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02131753","created_at":"2021-01-18T09:53:21.117Z","updated_at":"2024-07-02T16:35:48.422Z","phase":"Phase 2/3","brief_title":"Therapy Optimisation for the Treatment of Hairy Cell Leukemia","source_id_and_acronym":"NCT02131753","lead_sponsor":"University of Giessen","biomarkers":" CD19 • IL2RA • ITGAE • ISG20","pipe":"","alterations":" ","tags":["CD19 • IL2RA • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-10"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"d12d96b8-74ae-4497-a19e-62e5444280b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01384513","created_at":"2022-01-21T21:56:53.421Z","updated_at":"2024-07-02T16:36:00.226Z","phase":"Phase 2","brief_title":"A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies","source_id_and_acronym":"NCT01384513","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/04/2011","start_date":" 08/04/2011","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"7ef2e0f3-1263-4490-9b0d-ea0be571f605","acronym":"","url":"https://clinicaltrials.gov/study/NCT00489203","created_at":"2021-01-18T01:44:52.854Z","updated_at":"2025-02-25T16:22:35.314Z","phase":"Phase 2","brief_title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00489203","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2021-02-03"},{"id":"e4d83257-c80b-4e1e-8b12-fb24718335d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03739606","created_at":"2021-01-18T18:18:56.025Z","updated_at":"2024-07-02T16:36:37.235Z","phase":"Phase 2","brief_title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","source_id_and_acronym":"NCT03739606","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • IL3RA","pipe":" | ","alterations":" CD123 expression","tags":["PD-L1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/20/2020","start_date":" 10/20/2020","primary_txt":" Primary completion: 10/20/2020","primary_completion_date":" 10/20/2020","study_txt":" Completion: 10/20/2020","study_completion_date":" 10/20/2020","last_update_posted":"2020-12-17"},{"id":"a5412ef0-8de3-48a3-beec-bb96a1550b73","acronym":"MOXE","url":"https://clinicaltrials.gov/study/NCT03501615","created_at":"2021-01-18T17:13:55.556Z","updated_at":"2024-07-02T16:36:43.783Z","phase":"","brief_title":"An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT03501615 - MOXE","lead_sponsor":"AstraZeneca","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-06-29"},{"id":"2f7a5d93-470c-4333-bbd7-fc38933e1084","acronym":"PLAIT","url":"https://clinicaltrials.gov/study/NCT01829711","created_at":"2021-01-18T08:08:03.726Z","updated_at":"2024-07-02T16:36:46.386Z","phase":"Phase 3","brief_title":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","source_id_and_acronym":"NCT01829711 - PLAIT","lead_sponsor":"MedImmune LLC","biomarkers":" BRAF • CD22","pipe":"","alterations":" ","tags":["BRAF • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumoxiti (moxetumomab pasudotox)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/29/2013","start_date":" 04/29/2013","primary_txt":" Primary completion: 05/24/2017","primary_completion_date":" 05/24/2017","study_txt":" Completion: 04/29/2019","study_completion_date":" 04/29/2019","last_update_posted":"2020-04-08"},{"id":"19abf447-4689-4fc4-8eab-cc3dd49be351","acronym":"","url":"https://clinicaltrials.gov/study/NCT00040846","created_at":"2021-01-18T00:02:50.776Z","updated_at":"2024-07-02T16:36:50.764Z","phase":"Phase 2","brief_title":"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","source_id_and_acronym":"NCT00040846","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 11/01/2001","start_date":" 11/01/2001","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 12/01/2009","study_completion_date":" 12/01/2009","last_update_posted":"2020-01-29"}]